Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro

Journal of Cellular Biochemistry

Volumn 102, Issue 2, 2007, Pages 341-352

  Gramoun, Azza ^a   Shorey, Seema ^a   Bashutski, Jill D ^b,c   Dixon, S Jeffrey ^b   Sims, Stephen M ^b   Heersche, Johan N M ^a   Manolson, Morris F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti cancer therapy; Bone; Extracellular matrix; Integrin v 3; Osteoclast

Indexed keywords

CALCIUM; COLONY STIMULATING FACTOR 1; MONOCLONAL ANTIBODY LM 609; VITRONECTIN RECEPTOR; WORTMANNIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CALCIUM CELL LEVEL; CELL ADHESION; CELL COUNT; CELL FUNCTION; CELL FUSION; CELL STRUCTURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MELANOMA; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; RECEPTOR UPREGULATION; ANIMAL; BONE TUMOR; CELL CULTURE; CELL SHAPE; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR FLUID; IN VITRO STUDY; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; RABBIT;

ORYCTOLAGUS CUNICULUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; CALCIUM; CELL ADHESION; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; EXTRACELLULAR FLUID; INTEGRIN ALPHAVBETA3; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; PROTEIN CONFORMATION; RABBITS;

EID: 34948886119     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21296     Document Type: Article

References (47)

1. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
2. Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA. 2000. Peptidomimetic antagonists of αvβ3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 165:587-598.
3. Chambers TJ, Fuller K, Darby JA, Pringle JA, Horton MA. 1986. Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro. Bone Miner 1:127-135.
4. Davies J, Warwick J, Totty N, Philp R, Helfrich M, Horton M. 1989. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109:1817-1826.
5. Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V, Zallone A. 2002. Localization and possible role of two different αvβ3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci 115:2919-2929.
6. Faccio R, Grano M, Colucci S, Zallone AZ, Quaranta V, Pelletier AJ. 1998. Activation of αvβ3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun 249:522-525.
7. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. 2003. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin. J Cell Biol 162:499-509.
8. Feng X, Novack DV, Faccio R, Ory DS, Aya K, Boyer MI, McHugh KP, Ross FP, Teitelbaum SL. 2001. A Glanzmann's mutation in β3 integrin specifically impairs osteoclast function. J Clin Invest 107:1137-1144.
9. Frelinger AL 3rd, Du XP, Plow EF, Ginsberg MH. 1991. Monoclonal antibodies to ligand-occupied conformers of integrin αIIbβ3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 266:17106-17111.
10. Geiger B, Bershadsky A, Pankov R, Yamada KM. 2001. Transmembrane crosstalk between the extracellular matrix-cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2:793-805.
11. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA 2000. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res 6:3056-3061.
12. Horton MA. 1997. The αvβ3 integrin "vitronectin receptor". Int J Biochem Cell Biol 29:721-725.
13. Horton MA, Taylor ML, Arnett TR, Helfrich MH. 1991. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res 195:368-375.
14. Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687.
15. Kanehisa J, Heersche JN. 1988. Osteoclastic bone resorption: In vitro analysis of the rate of resorption and migration of individual osteoclasts. Bone 9:73-79.
16. Kim M, Carman CV, Springer TA. 2003. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 301:1720-1725.
17. i in large (≥10 nuclei) and small (≤5 nuclei) osteoclasts. Am J Physiol Cell Physiol 279:0751-761.
18. Lees RL, Sabharwal VK, Heersche JN. 2001. Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28:187-194.
19. Legier DF, Wiedle G, Ross FP, Imhof BA. 2001. Superactivation of integrin αvβ3 by low antagonist concentrations. J Cell Sci 114:1545-1553.
20. Manolagas SC. 2000. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrnol Rev 21:115-137.
21. Masarachia P, Yamamoto M, Leu CT, Rodan G, Duong L. 1998. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. Endocrinology 139:1401-1410.
22. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. 2000. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
23. Meissner RS, Perkins JJ, Duong le T, Hartman GD, Hoffman WF, Huff JR, Ihle NC, Leu CT, Nagy RM, Naylor-Olsen A, Rodan GA, Rodan SB, Whitman DB, Wesolowski GA, Duggan ME. 2002. Nonpeptide αvβ3 antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide. Bioorg Med Chem Lett 12:25-29.
24. Mikecz K. 2000. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 1:199-203.
25. Miyamoto T, Arai F, Ohneda O, Takagi K, Anderson DM, Suda T. 2000. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand. Blood 96:4335-4343.
26. Mould AP, Askari JA, Barton S, Kline AD, McEwan PA, Craig SE, Humphries MJ. 2002. Integrin activation involves a conformational change in the α 1 helix of the β subunit A-domain. J Biol Chem 277:19800-19805.
27. Mullan RH, Bresnihan B. 2003. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. Clin Exp Rheumatol 21:S158-164.
28. Nakamura I, Gailit J, Sasaki T. 1996. Osteoclast integrin αvβ3 is present in the clear zone and contributes to cellular polarization. Cell Tissue Res 286:507-515.
29. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT. 1999. Role of αvβ3 integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 112:3985-3993.
30. Nakamura I, Tanaka H, Rodan GA, Duong LT. 1998. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 139:5182-5193.
31. Palacio S, Felix R. 2001. The role of phosphoinositide 3-kinase in spreading osteoclasts induced by colony-stimulating factor-1. Eur J Endocrinol 144:431-440.
32. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. 2001. Pilot study of vitaxin-an angiogenesis inhibitor in patients with advanced leiomyosarcomas. Cancer 92:1347-1348.
33. Pelletier AJ, Kunicki T, Ruggeri ZM, Quaranta V. 1995. The activation state of the integrin αIIbβ3 affects outside-in signals leading to cell spreading and focal adhesion kinase phosphorylation. J Biol Chem 270:18133-18140.
34. Pilkington MF, Sims SM, Dixon SJ. 1998. Wortmannin inhibits spreading and chemotaxis of rat osteoclasts in vitro. J Bone Miner Res 13:688-694.
35. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. 2001. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132.
36. Shibutani T, Heersche JN. 1993. Effect of medium pH on osteoclast activity and osteoclast formation in cultures of dispersed rabbit osteoclasts. J Bone Miner Res 8:331-336.
37. Shorey S, Heersche JN, Manolson MF. 2004. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula. Bone 35:909-917.
38. Spillmann C, Osorio D, Waugh R. 2002. Integrin activation by divalent ions affects neutrophil homotypic adhesion. Ann Biomed Eng 30:1002-1011.
39. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
40. Teti A, Taranta A, Migliaccio S, Degiorgi A, Santandrea E, Villanova I, Faraggiana T, Chellaiah M, Hruska KA. 1998. Colony stimulating factor-1-induced osteoclast spreading depends on substrate and requires the vitronectin receptor and the c-src proto-oncogene. J Bone Miner Res 13:50-58.
41. Trebec DP, Chandra D, Gramoun A, Li K, Heersche JNM, Manolson MF., 2007. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem. [Epub ahead of print]. DOI: 10.1002/jcb.21171.
42. Tucker GC. 2006. Integrins: Molecular targets in cancer therapy. Curr Oncol Rep 8:96-103.
43. van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Lowik C. 1994. Integrins and osteoclastic resorption in three bone organ cultures: Differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. J Bone Miner Res 9:1021-1028.
44. Wilder RL. 2002. Integrin αvβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61: Suppl (2):ii96-ii99.
45. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD. 1998. Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb. Proc Natl Acad Sci USA 95:6037-6042.
46. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. 2001. Crystal structure of the extracellular segment of integrin αvβ3. Science 294:339-345.
47. Xiong JP, Stehle T, Zhang R, Joachimiak A, Freeh M, Goodman SL, Arnaout MA 2002. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 296:151-155.